Posted: December 21, 2024 at 2:55 am
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments.
Read the original here:
Aridis Provides Corporate Update
Posted: December 21, 2024 at 2:55 am
LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that it will hold its annual general and special meeting of shareholders (the “Meeting”) on Friday, January 10, 2025, at 1:00pm ET. Due to the recent postal strike in Canada, the Meeting, which had originally been scheduled to be held on January 7, 2025, at 1:00pm ET, was postponed so that Sernova and its agents are able to complete the mailing of its meeting materials through Canada Post to meet regulatory requirements.
Read the original post:
Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025
Posted: December 21, 2024 at 2:54 am
SYDNEY, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate its First-In-Human (FIH) Phase 1 therapeutic clinical study of 177Lu-labelled RAD 202 for the treatment of HER2-expressing solid tumors.
Follow this link:
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Posted: December 21, 2024 at 2:54 am
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan.
Read more from the original source:
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid...
Posted: December 21, 2024 at 2:54 am
COPENHAGEN, Denmark and NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating, off-the-shelf therapeutic cancer vaccines today announced that it has entered into a loan facility of up to €57.5 million from the European Investment Bank (EIB), the long-term lending institution of the European Union owned by its Member States. The debt facility includes three committed tranches totaling up to €37.5 million, which will become available if the company satisfies certain conditions, and one uncommitted accordion tranche of €20 million. The company expects the first two tranches to be available for disbursement in the first quarter of 2025.
See the rest here:
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
Posted: December 21, 2024 at 2:54 am
Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions
Excerpt from:
Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection
Posted: December 21, 2024 at 2:54 am
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical’s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy.
Posted: December 21, 2024 at 2:54 am
DXS INTERNATIONAL PLC
Read the original:
Result of AGM
Posted: December 21, 2024 at 2:54 am
News Release
Read this article:
Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care
